Patents by Inventor Santiago CORREA

Santiago CORREA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240180825
    Abstract: An injectable hydrogel network is provided distinguishing a non-covalently cross-linked hydrogel network with polymers functionalized with hydrophobic fatty pendant groups hydrophobically cross-linked with liposomal nanoparticles in which the liposomal nanoparticles are the cross-linkers. As the hydrogel is injectable, it is easily administered under the skin and does not require invasive surgical implantation. After injection the hydrogel rapidly self-heals to form a robust solid-like depot that can persist in the body over relevant timescales. The material does not cause a negative immune response like many other materials do. The hydrogel can gradually degrade over time in the body and therefore would not require surgical removal.
    Type: Application
    Filed: April 19, 2022
    Publication date: June 6, 2024
    Inventors: Santiago Correa, John Klich, Eric Andrew Appel
  • Patent number: 11964026
    Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: April 23, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Antonio Eric Barberio, Santiago Correa Echavarria, Mariane Bandeira Melo, Talar Tokatlian, Erik Christopher Dreaden, Paula T. Hammond, Darrell J. Irvine
  • Publication number: 20240032513
    Abstract: Preclinical cancer research is heavily dependent on allograft and xenograft models, but current approaches to tumor inoculation yield inconsistent tumor formation and growth, ultimately wasting valuable resources (e.g., animals, time, and money) and limiting experimental progress. A method and kit for tumor inoculation is disclosed using self-assembled hydrogels to reliably generate tumors with low variance in growth. The observed reduction in model variance enables smaller animal cohorts, improved effect observation and higher-powered studies.
    Type: Application
    Filed: October 20, 2021
    Publication date: February 1, 2024
    Inventors: Abigail Kate Grosskopf, Eric Andrew Appel, Santiago Correa
  • Publication number: 20230201367
    Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.
    Type: Application
    Filed: August 22, 2022
    Publication date: June 29, 2023
    Inventors: Antonio E. Barberio, Santiago Correa Echavarria, Mariane Bandeira Melo, Talar Tokatlian, Erik Christopher Dreaden, Paula T. Hammond, Darrell J. Irvine
  • Patent number: 11419947
    Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: August 23, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Antonio Eric Barberio, Santiago Correa Echavarria, Mariane Bandeira Melo, Talar Tokatlian, Erik Christopher Dreaden, Paula T. Hammond, Darrell J. Irvine
  • Publication number: 20210338801
    Abstract: An immunomodulatory delivery system includes a hydrogel, a first immunomodulatory cargo encapsulated in the cargo, and a second immunomodulatory cargo encapsulated in the hydrogel. The hydrogel includes a polymer non-covalently crossed-linked with a plurality of nanoparticles. The first immunomodulatory cargo is smaller than the second immunomodulatory cargo. A ratio of a diffusivity of the first immunomodulatory cargo through the hydrogel to a diffusivity of the second immunomodulatory cargo through the hydrogel is less than 3.
    Type: Application
    Filed: October 1, 2019
    Publication date: November 4, 2021
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Gillie A. ROTH, Eric Andrew APPEL, Mark DAVIS, Emily C. GALE, Santiago CORREA
  • Publication number: 20190125895
    Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.
    Type: Application
    Filed: October 30, 2018
    Publication date: May 2, 2019
    Inventors: Antonio Eric Barberio, Santiago Correa Echavarria, Mariane Bandeira Melo, Talar Tokatlian, Erik Christopher Dreaden, Paula T. Hammond, Darrell J. Irvine